TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37084104

Group type: EXPERIMENTAL
Intervention: Enhanced Friendship Bench (EFB) intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 37084132

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 15
Study: 37084140

Group type: EXPERIMENTAL
Intervention: eEF2 (elongation factor-2) as a biomarker
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proteomic analysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Regulatory mechanisms of eEF2
Number of subjects: 40
Study: 37084261

Group type: EXPERIMENTAL
Intervention: Intrathecal oxytocin, 100 µg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5
Study: 37084329

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 0
Study: 37084342

Group type: EXPERIMENTAL
Intervention: Elafibranor 120 mg daily for 12 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Elafibranor 80 mg daily for 12 weeks
Number of subjects: 10
Study: 37084383

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical BMT with posttransplantation cyclophosphamide (PTCy) and 400 cGy total body irradiation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lower dose total body irradiation (200 cGy)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HLA-haploidentical BMT with PTCy
Number of subjects: 27
Study: 37084401

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional therapy (active vitamin D and phosphate)
Number of subjects: 61
Study: 37084590

Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet including cooked soybeans (1/2 cup [86 g]/day) for 12 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual diet for 12 weeks
Number of subjects: 84
Study: 37084629

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: k-nearest neighbor (kNN)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: MultiLayer Perceptron (MLP)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Ensemble feature selection
Number of subjects: 522
Study: 37084748

Group type: EXPERIMENTAL
Intervention: Proton therapy (54 Gy with a 0.5 cm clinical target volume margin) combined with limited surgery
Number of subjects: 94
Study: 37084803

Group type: EXPERIMENTAL
Intervention: AGuIX®-based radiation treatments
Number of subjects: 4
Study: 37084814

Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 37085287

Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg followed by boluses of 40 mg every 6 hours and infusion of 2 mg/hour
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Weight-based ropivacaine dosing
Number of subjects: 15
Study: 37085328

Group type: EXPERIMENTAL
Intervention: Informant report measured with the Cognitive Difficulties Scale (IMAP+) and Everyday Cognition (ADNI) in patients with mild cognitive impairment (MCI)
Number of subjects: 841

Group type: COMPARATOR
Intervention: Informant report in cognitively unimpaired older individuals (controls)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Informant report in patients with subjective cognitive decline (SCD)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Informant report in patients with Alzheimer-type dementia (AD dementia)
Number of subjects: 841
Study: 37085451

Group type: EXPERIMENTAL
Intervention: HepB-CpG (HEPLISAV-B)
Number of subjects: 147

Group type: COMPARATOR
Intervention: HepB-Eng (Engerix-B)
Number of subjects: 147
Study: 37085523

Group type: EXPERIMENTAL
Intervention: Human milk-based fortifiers (HMBF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bovine milk-based fortifiers (BMBF)
Number of subjects: 0
Study: 37085651

Group type: EXPERIMENTAL
Intervention: Spanish version of the Tilburg Frailty Indicator (TFI)
Number of subjects: 457
Study: 37085674

Group type: EXPERIMENTAL
Intervention: GSTA1*A*A
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GSTA1*A*B
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GSTA1*B*B
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GSTA1 polymorphism
Number of subjects: 60
Study: 37085731

Group type: EXPERIMENTAL
Intervention: IVIM parameters (ADC, D, f) in LVI-positive group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined parameter (D + f + thickness)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ADC, D, f
Number of subjects: 90
Study: 37085759

Group type: EXPERIMENTAL
Intervention: TalkingMats
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Conversation Method
Number of subjects: 0
Study: 37085812

Group type: EXPERIMENTAL
Intervention: Ileal pouch anal anastomosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ileorectal anastomosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients declining reconstruction or not eligible for both methods)
Number of subjects: 0
Study: 37085833

Group type: EXPERIMENTAL
Intervention: Piezo-electric instruments
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional drilling burs
Number of subjects: 22
Study: 37085849

Group type: EXPERIMENTAL
Intervention: Transcriptomic score (TScore)
Number of subjects: 176
Study: 37085862

Group type: EXPERIMENTAL
Intervention: Exome sequencing (ES) diagnostic test for ID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis with price decrease of 20% for the capture kit and 50% for the sequencing support kit
Number of subjects: 0
Study: 37085877

Group type: EXPERIMENTAL
Intervention: PRECIS-2 ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRECIS-2 wheels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up/data collection domain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAPICE qualitative approach
Number of subjects: 0
Study: 37085880

Group type: EXPERIMENTAL
Intervention: Anticholinergic bladder therapy (tolterodine 2 mg ER)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Beta-3 adrenergic agonist bladder therapy (mirabegron 25 mg ER)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 37085899

Group type: EXPERIMENTAL
Intervention: Meals delivered daily to participants' homes by a volunteer or paid driver who socializes with the client
Number of subjects: 243

Group type: COMPARATOR
Intervention: Frozen meals that are mailed to participants' homes
Number of subjects: 243
Study: 37085935

Group type: EXPERIMENTAL
Intervention: Normal levels of cardiorespiratory fitness (CRF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low levels of cardiorespiratory fitness (CRF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Age, fatmass, and physical activity level
Number of subjects: 60
Study: 37086054

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTI)
Number of subjects: 58
Study: 37086055

Group type: COMPARATOR
Intervention: Bed provision and sleep education (BfK program)
Number of subjects: 27
Study: 37086083

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients without antihypertensives
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients without a patent foramen ovale (PFO)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients after excluding those in the first tertile of delay between stroke and ABPM
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Non-dipping patterns of BP in participants with a PFO
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Non-dipping patterns of BP in participants without hypertension
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Nocturnal non-dipping patterns of blood pressure
Number of subjects: 238
Study: 37086209

Group type: EXPERIMENTAL
Intervention: Individuals with bronchiectasis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 37086257

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 706

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 706
Study: 37086340

Group type: COMPARATOR
Intervention: DMT fumarate (SPL026) administered via a two-phase intravenous (IV) infusion, escalating doses of 9-21.5 mg (DMT freebase) over a 10-min infusion.
Number of subjects: 24
Study: 37086362

Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard care control arm
Number of subjects: 61
Study: 37086568

Group type: EXPERIMENTAL
Intervention: N-acetyl aspartate (NAA) measured by MRS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Glutamine/glutamate/GABA measured by MRS
Number of subjects: 27
Study: 37086595

Group type: EXPERIMENTAL
Intervention: LEN+PEMBRO (Lenvatinib 20 mg/day + Pembrolizumab 200 mg Q3W)
Number of subjects: 827

Group type: COMPARATOR
Intervention: TPC (Treatment of Physician's Choice, doxorubicin 60 mg/m2)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: LEN+PEMBRO
Number of subjects: 827

Group type: COMPARATOR
Intervention: TPC
Number of subjects: 827
Study: 37086614

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (energy and protein intakes)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Trace element monitoring
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hospital mortality
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Length of ICU stay
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 35
Study: 37086618

Group type: EXPERIMENTAL
Intervention: EVEN protein intake (30% at each main meal)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SKEWED protein intake (15% at breakfast and lunch, 60% at dinner)
Number of subjects: 24
Study: 37086745

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5.4 mg/kg intravenously once every 3 weeks)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Treatment of physician's choice (capecitabine 1250 mg/m2)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 608

Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 608
Study: 37086854

Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI) in clean-contaminated cases
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI) in contaminated-dirty cases
Number of subjects: 335

Group type: COMPARATOR
Intervention: Clean-contaminated cases
Number of subjects: 335

Group type: COMPARATOR
Intervention: Contaminated-dirty cases
Number of subjects: 335

Group type: COMPARATOR
Intervention: Inpatient costs after clean-contaminated surgery
Number of subjects: 335

Group type: COMPARATOR
Intervention: Inpatient costs after contaminated-dirty surgery
Number of subjects: 335
Study: 37086916

Group type: EXPERIMENTAL
Intervention: Minimal intervention including a Fitbit linked with clinic's patient portal and EHR with weekly feedback
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Online gym (step-up condition for non-responders)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Coaching calls (step-up condition for non-responders)
Number of subjects: 323
Study: 37087308

Group type: EXPERIMENTAL
Intervention: Manual analysis by core laboratory (CL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) algorithm
Number of subjects: 0
Study: 37087332

Group type: EXPERIMENTAL
Intervention: Educational intervention on perioperative neuromuscular block management
Number of subjects: 2314
Study: 37087399

Group type: EXPERIMENTAL
Intervention: Axitinib modifications (dose reduction or treatment interruption)
Number of subjects: 219

Group type: COMPARATOR
Intervention: No modifications
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Axitinib modifications
Number of subjects: 219
Study: 37087424

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MCT)
Number of subjects: 61
Study: 37087437

Group type: EXPERIMENTAL
Intervention: Family Talk Preventive Intervention
Number of subjects: 286

Group type: COMPARATOR
Intervention: Service as usual
Number of subjects: 286
Study: 37087459

Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Weekly Abatacept + Methotrexate
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Abatacept Monotherapy
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: De-escalated/Withdraw Abatacept
Number of subjects: 752

Group type: COMPARATOR
Intervention: Abatacept Placebo + Methotrexate
Number of subjects: 752
Study: 37087470

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 9
Study: 37087709

Group type: EXPERIMENTAL
Intervention: Free-viewing phase in MDD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free-viewing phase in healthy controls (HC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined fMRI and eye-tracking measurements
Number of subjects: 0
Study: 37087950

Group type: EXPERIMENTAL
Intervention: ide-cel treatment
Number of subjects: 45
Study: 37088093

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 288

Group type: COMPARATOR
Intervention: Lifestyle modification plus best medical care
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (per protocol analysis)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (per protocol analysis)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Lifestyle modification plus best medical care (per protocol analysis)
Number of subjects: 288
Study: 37088096

Group type: EXPERIMENTAL
Intervention: BNT162b2 OMI BA.1 boost (Ad/P)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: BNT162b2 OMI BA.1 boost (mRNA/P)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 boost (Ad/M)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 boost (mRNA/M)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Comparison between Ad/P and mRNA/P
Number of subjects: 187

Group type: COMPARATOR
Intervention: Comparison between Ad/M and mRNA/M
Number of subjects: 187
Study: 37088107

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 11
Study: 37088129

Group type: EXPERIMENTAL
Intervention: RI-AIR program (evidence-based school- and/or home-based asthma management interventions)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: School-based interventions (child and caregiver education programs, school staff trainings)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Home-based interventions (individualized asthma education, home-environmental assessments, strategies and supplies for trigger remediation)
Number of subjects: 433
Study: 37088275

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (Dexcom G6 Pro) for 10 days starting at the 50-g glucose challenge test.
Number of subjects: 136
Study: 37088280

Group type: EXPERIMENTAL
Intervention: Lowest quartile of APOA-1
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 10-unit decrease of APOA-1
Number of subjects: 310
Study: 37088310

Group type: EXPERIMENTAL
Intervention: High target mean arterial pressure (H-MAP) 80-85 mmHg
Number of subjects: 150
Study: 37088311

Group type: EXPERIMENTAL
Intervention: ELF test
Number of subjects: 3378

Group type: COMPARATOR
Intervention: FIB-4
Number of subjects: 3378

Group type: COMPARATOR
Intervention: NFS
Number of subjects: 3378

Group type: EXPERIMENTAL
Intervention: FIB-4 followed by ELF
Number of subjects: 3378
Study: 37088312

Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX for 12 weeks (Group A)
Number of subjects: 315

Group type: COMPARATOR
Intervention: SOF/VEL/VOX + weight-based ribavirin for 12 weeks (Group B)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX (Group A)
Number of subjects: 315

Group type: COMPARATOR
Intervention: SOF/VEL/VOX + ribavirin (Group B)
Number of subjects: 315
Study: 37088337

Group type: EXPERIMENTAL
Intervention: HT MCS (Mechanical Circulatory Support)
Number of subjects: 276

Group type: COMPARATOR
Intervention: HT non-MCS (Awaiting transplant without MCS)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Prior to long-term MCS
Number of subjects: 276
Study: 37088376

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study: 37088401

Group type: EXPERIMENTAL
Intervention: Double umbilical cord blood transplantation (dUCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HLA-haploidentical bone marrow transplantation (haplo-BMT)
Number of subjects: 0
Study: 37088447

Group type: EXPERIMENTAL
Intervention: Surgery (PPV, subretinal tPA [maximum, 0.5 ml/50 μg], and 20% sulfur hexafluoride)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pneumatic displacement (PD) with tPA and VEGF inhibitor
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (Surgery and PD)
Number of subjects: 90
Study: 37088457

Group type: EXPERIMENTAL
Intervention: Pegbelfermin (10, 20, or 40 mg)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 37088458

Group type: EXPERIMENTAL
Intervention: Pegbelfermin (10, 20, or 40 mg) injected subcutaneously once weekly for 48 weeks
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo injected subcutaneously once weekly for 48 weeks
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pegbelfermin (10, 20, or 40 mg)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pegbelfermin (20 or 40 mg)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pegbelfermin
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 40-mg pegbelfermin
Number of subjects: 155
Study: 37088866

Group type: EXPERIMENTAL
Intervention: Restorex penile traction therapy (RxPTT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No treatment (Tx)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Crossover to Tx (Group 2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Crossover to no treatment after initial treatment (Group 3)
Number of subjects: 82
Study: 37088964

Group type: EXPERIMENTAL
Intervention: 4CMenB and MenACWY vaccines
Number of subjects: 55
Study: 37089721

Group type: EXPERIMENTAL
Intervention: Systemic and topical medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative evaluation study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future studies
Number of subjects: 0
Study: 37089722

Group type: EXPERIMENTAL
Intervention: Blended group body psychotherapy (BPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting-period comparator
Number of subjects: 40
Study: 37089863

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic immune suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LRG1 as a potential target and biomarker
Number of subjects: 0
Study: 37090002

Group type: EXPERIMENTAL
Intervention: Digital CBTi
Number of subjects: 77
Study: 37090015

Group type: EXPERIMENTAL
Intervention: MISSION-Vet intervention
Number of subjects: 42
Study: 37090089

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapies (LLTs)
Number of subjects: 9044
Study: 37090123

Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging (LSCI)
Number of subjects: 4
Study: 37090129

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D) population in Japan
Number of subjects: 800
Study: 37090438

Group type: EXPERIMENTAL
Intervention: Regorafenib plus nivolumab
Number of subjects: 70
Study: 37090440

Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg with ezetimibe 10 mg)
Number of subjects: 3780

Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy
Number of subjects: 3780

Group type: COMPARATOR
Intervention: High-intensity statin monotherapy (rosuvastatin 20 mg)
Number of subjects: 3780
Study: 37090566

Group type: EXPERIMENTAL
Intervention: CARE-CITE-Gait intervention
Number of subjects: 15
Study: 37090860

Group type: EXPERIMENTAL
Intervention: NEUROMARK® system (radiofrequency ablation to the posterior nasal nerves)
Number of subjects: 36
Study: 37090974

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT-A)
Number of subjects: 86
Study: 37091033

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study: 37091450

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) based parameters: Mean Flow Velocity (MFV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) based parameters: Pulsatility Index (PI)
Number of subjects: 0
Study: 37091505

Group type: EXPERIMENTAL
Intervention: Intraoperative assessment of flap perfusion using ICG-NIR-FA
Number of subjects: 280

Group type: COMPARATOR
Intervention: Regular clinical parameters only (Control)
Number of subjects: 280
Study: 37091508

Group type: EXPERIMENTAL
Intervention: Online opioid overdose education and remote distribution of naloxone kits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information on where to obtain a naloxone kit
Number of subjects: 0
Study: 37091509

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy group prenatal care model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Number of subjects: 0
Study: 37091507

Group type: EXPERIMENTAL
Intervention: Family-based financial incentive intervention for cigarette smoking cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-incentives control condition
Number of subjects: 0
Study: 37091538

Group type: EXPERIMENTAL
Intervention: TFT-TFS program implementation
Number of subjects: 219